FILGRASTIM (R-METHUG-CSF) IN CLINICAL PRACTICE, SECOND EDITION

Providing a wealth of insights drawn from the experience of groundbreaking researchers working in the field, this Second Edition of a landmark volume brings preclinical and clinical studies of Filgrastim (r-metHuG-CSF) up to date with completely revised and expanded discussions of its biology, biochemistry, structure, pharmacology, clinical applications, and pharmacoeconomics.
Explores how Filgrastim reduces infectious complications in the management of cancer, AIDS, severe chronic neutropenia, neutropenia associated with nonmalignant autoimmune diseases, non-neutropenic infections, lymphoma, leukemia, diabetic foot infection, and more!
Now enhanced with 13 new chapters, Filgrastim (r-metHuG-CSF) in Clinical Practice, Second Edition features novel research as well as provocative and enhanced information on

pharmacokinetic-pharmacodynamic modeling to delineate concentration-response relationships

Filgrastim as treatment or prophylaxis for decreasing infectious episodes, intensifying immunosuppresive therapy, and mobilizing progenitor stem cells

improving granulocyte collection yields from normal donors and neutrophil transfusions in recipients of such products

the potential of peripheral blood progenitor cell (PBPC) transplantation in diseases, such as rheumatoid arthritis

maintaining optimal chemotherapy intensity in situations where dose reduction or delay is necessary

combining Filgrastim with various cytokines, including granulocyte-macrophage colony-stimulating factor, stem-cell factor, rHuSCF, IL-3, and erythropoietin

Filgrastim's toxicity profile, daily aspects of administration, economic impact, and effect on patients' quality of life

and much more!
Containing over 1650 references-more than 600 new to this edition!-this truly outstanding Second Edition continues to furnish unparalleled coverage of the subject matter for oncologists, hematologists, infectious disease specialists, immunologists, radiotherapists, oncological nurses, and graduate and medical school students in these disciplines.

The Biology, Biochemistry, and Pharmacology of G-CSF

Biology of G-CSF, Graham Molineux and T. Michael Dexter
Biochemistry and Structure of Filgrastim (r-metHuG-CSF), Timothy Osslund and Thomas C. Boone
Pharmacology of Filgrastim (r-metHuG-CSF), Lorin K. Roskos, Ellen N. Cheung, Martha Vincent, MaryAnn Foote, and George Morstyn
Use of Filgrastim (r-metHuG-CSF) to Enhance Fc Receptor Function, Thomas Valerius, Bernhard Stockmeyer, and J. G. J. van de Winkel

Causes and Treatment of Neutropenia

Causes, Clinical Consequences, and Treatment of Neutropenia, W. Conrad Liles and David C. Dale
Use of Filgrastim (r-metHuG-CSF) in Severe Chronic Neutropenia, David C. Dale, Carol Fier, and Karl Welte
Use of Filgrastim (r-metHuG-CSF) in Neutrophil Transfusions, Douglas R. Adkins, Randy A. Brown, Lawrence T. Goodnough, and John F. DiPersio

Use of Filgrastim in Oncology Settings

The Importance of Dose in Cancer Chemotherapy and the Role of Hematopoietic Growth Factors, Miguel H. Bronchud
Use of Filgrastim (r-metHuG-CSF) in the Treatment of Lung Cancer, Jeffrey Crawford and MaryAnn Foote
Filgrastim (r-metHuG-CSF) in Lymphoma, Janice Gabrilove
Using Filgrastim (r-metHuG-CSF) in the Treatment of Breast Cancer, Irene Kuter
Filgrastim (r-metHuG-CSF) in Bone Marrow Transplantation, William P. Sheridan
Filgrastim (r-metHuG-CSF) in Autologous Peripheral Blood Cell Transplantation, Norbert Schmitz and Peter Dreger
Allogeneic Peripheral Blood Progenitor Cell Transplantation, William I. Bensinger and C. Dean Buckner
The Role of Filgrastim (r-metHuG-CSF) in the Treatment of Testicular Cancer, Craig Nichols and Scott Saxman
Use of Myeloid Hematopoietic Growth Factors in AIDS-Related Malignancies, Fa-Chyi Lee and Ronald T. Mitsuyasu
Use of Hematopoietic Colony-Stimulating Factors in the Early Clinical Development of New Anticancer Drugs, Eric Keith Rowinsky
Use of Combinations of Cytokines with Filgrastim (r-metHuG-CSF), Juan W. Valle and J. Howard Scarffe

Use of Filgrastim in Infectious Disease Settings

Immunomodulatory Properties of Filgrastim (r-metHuG-CSF) in Preclinical Models, Thomas Hartung and Albrecht Wendel
Filgrastim (r-metHuG-CSF) in Pneumonia, Jeff Andresen, Hassan Movahhed, and Steve Nelson
Use of Filgrastim (r-metHuG-CSF) in Human Immunodeficiency Virus Infection, David L. Pitrak
Neonatal Sepsis-An Unsolved Problem, Prabhakar Kocherlakota, Edmund F. LaGamma, Magdy Ahmad, Candace Breen, Marc G. Golightly, and Howard B. Fleit

Use of Filgrastim in Hematologic Malignancies

Filgrastim (r-metHuG-CSF) for the Treatment of Myelodysplastic Syndromes, Robert S. Negrin and Peter L. Greenberg
Use of Filgrastim (r-metHuG-CSF) in Acute Myeloid Leukemia, Gerhard Heil and Alan J. Barge
Use of Filgrastim (r-metHuG-CSF) in Aplastic Anemia, Aruna Raghavachar, Andrea Bacigalupo, and Hubert Schrezenmeier

Use of Filgrastim in Other Settings

Use of Filgrastim (r-metHuG-CSF) in Autoimmune Disease, Roland P. Repp, Gisela Helm, and J. G. J. van de Winkel
Treatment of Diabetic Foot Ulcers and Infection with Filgrastim (r-metHuG-CSF), Andrew Gough and Michael Edmonds

Safety and Administration of Filgrastim

Safety Profile of Filgrastim (r-metHuG-CSF), Karen L. Patterson, Shirley Y. Masuda, and Sherri L. Brown
Practical Aspects of Filgrastim (r-metHuG-CSF) Administration, Jane Campbell

Quality of Life and Economic Studies

Modeling Cost-Effective Use of Filgrastim (r-metHuG-CSF) in the Treatment of Patients with Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy, Jeffrey H. Silber, Moshe Fridman, and M. Haim Erder